LGALS3 and prostate carcinoma: A prospective clinical study analyzed Galectin-3 and prostate specific antigen (PSA) (and their respective autoantibodies) levels in the serum and described positive associations between Galectin-3 and PSA levels in 76 men with different stages of prostate cancer and in 19 healthy control individuals (45, 46).